Abstract:Data on the pharmacological management of acute agitation in schizophrenia are scarce. The aim of this study is to investigate the prescription practices in the treatment of agitation in Chinese patients with schizophrenia. We conducted a large, multicenter, observational study in 14 psychiatry hospitals in China. Newly hospitalized schizophrenia patients with the PANSS-EC total score ≥ 14 and a value ≥4 on at least one of its five items were included in the study. Their drug treatments of the first 2 weeks in hospital were recorded by the researchers. Eight hundred and 53 patients enrolled in and 847 (99.30%) completed the study. All participants were prescribed antipsychotics, 40 (4.72%) were prescribed benzodiazepine in conjunction with antipsychotics and 81 were treated with modified electric convulsive therapy (MECT). Four hundred and 12 (48.64%) patients were prescribed only one antipsychotic, in the order of olanzapine (120 patients, 29.13%), followed by risperidone (101 patients, 24.51%) and clozapine (41 patients, 9.95%). About 435 (51.36%) participants received antipsychotic polypharmacy, mostly haloperidol + risperidone (23.45%), haloperidol+ olanzapine (17.01%), olanzapine+ ziprasidone (5.30%), haloperidol + clozapine (4.37%) and haloperidol + quetiapine (3.90%). Binary logistic regression analysis suggests that a high BARS score (OR 2.091, 95%CI 1.140–3.124), severe agitation (OR 1.846, 95%CL 1.266–2.693), unemployment or retirement (OR 1.614, 95%CL 1.189–2.190) and aggressiveness on baseline (OR 1.469, 95%CL 1.032–2.091) were related to an increased antipsychotic polypharmacy odds. Male sex (OR 0.592, 95%CL 0.436–0.803) and schizophrenia in older persons (age ≥ 55 years, OR 0.466, 95%CL 0.240–0.902) were less likely to be associated with antipsychotic polypharmacy. The present study demonstrates that monotherapy and polypharmacy display equally common patterns of antipsychotic usage in managing agitation associated with schizophrenia in China. The extent and behavioral activities of agitation and several other factors were associated with polypharmacy.

Common Use of Anticholinergic Medications in Older Patients with Schizophrenia: Findings of the Research on Asian Psychotropic Prescription Pattern (REAP) Study, 2001–2009

Use of Anticholinergic Drugs in Patients with Schizophrenia in Asia from 2001 to 2009

Anticholinergic Use Trends in 14,013 Patients with Schizophrenia from Three National Surveys on the Use of Psychotropic Medications in China (2002–2012)

Common use of antipsychotic polypharmacy in older Asian patients with schizophrenia (2001-2009).

Prescribing Patterns of Low Doses of Antipsychotic Medications in Older Asian Patients with Schizophrenia, 2001–2009

Use of first- and second-generation antipsychotic medications in older patients with schizophrenia in Asia (2001-2009).

Common use of high doses of antipsychotic medications in older Asian patients with schizophrenia (2001-2009).

Antipsychotic Treatment in Older Schizophrenia Patients with Extrapyramidal Side Effects in Asia (2001 - 2009).

Prescribing antipsychotic drugs for inpatients with schizophrenia in Asia: Comparison of REAP-2001 and REAP-2004 studies: Prescribing antipsychotics in REAP study

Use of Clozapine in Older Asian Patients with Schizophrenia Between 2001 and 2009

Adjunctive Antidepressant Prescriptions for Hospitalized Patients with Schizophrenia in Asia (20012009)

Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009).

Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in China.

Adjunctive Antidepressant Use In Schizophrenia In China: A National Survey (2002-2012)

Concurrent Antipsychotic Use in Older Adults Treated with Antidepressants in Asia

Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change.

Patterns of Long Acting Injectable Antipsychotic Use and Associated Clinical Factors in Schizophrenia among 15 Asian Countries and Region

High Dose Antipsychotic Use in Schizophrenia: Findings of the REAP (research on East Asia Psychotropic Prescriptions) Study

Prescription Practices in the Treatment of Agitation in Newly Hospitalized Chinese Schizophrenia Patients: Data from a Non-Interventional Naturalistic Study

Adjunctive Benzodiazepine Treatment Of Hospitalized Schizophrenia Patients In Asia From 2001 To 2008

Prevalence of strong anticholinergic use in residents with and without cognitive impairment and frailty: Analysis from 106 nursing homes in 12 Asia-Pacific and European countries